Similar articles

• Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.

  John JE. John JE. Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14. Drug Discov Today. 2011. PMID: 22020052 No abstract available.
• The role of academic institutions in the development of drugs for rare and neglected diseases.

  Coles LD, Cloyd JC. Coles LD, et al. Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4. Clin Pharmacol Ther. 2012. PMID: 22760003 Review.
• A new era of hope for the world's most neglected diseases.

  The PLoS Medicine Editors. The PLoS Medicine Editors. PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8. PLoS Med. 2005. PMID: 16138790 Free PMC article.
• The European rare diseases therapeutic initiative.

  Fischer A, Borensztein P, Roussel C. Fischer A, et al. PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23. PLoS Med. 2005. PMID: 16104832 Free PMC article.
• In silico repositioning of approved drugs for rare and neglected diseases.

  Ekins S, Williams AJ, Krasowski MD, Freundlich JS. Ekins S, et al. Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1. Drug Discov Today. 2011. PMID: 21376136 Review.